Why Wattle Health Australia Ltd shares are in a trading halt

The Wattle Health Australia Ltd (ASX: WHA) share price won’t be going anywhere on Friday after the baby food and infant formula company requested that its shares be placed in a trading halt.

Wattle Health’s shares will remain in a trading halt until the sooner of the market open on Tuesday January 16 or the release of an announcement.

Why are its shares in a trading halt?

According to the request, Wattle Health’s shares are in a trading halt pending the release of a material announcement in relation to a new product accreditation arrangement.

The only product accreditation that the company is seeking, that I am aware of, is the CFDA accreditation for its infant formula products.

Following the introduction of strict new regulations on January 1, CFDA accreditation is now required in order to sell infant formula products in the lucrative Chinese market.

A2 Milk Company Ltd (ASX: A2M) is the only other listed Australian company with this accreditation at present. Rival Bellamy’s Australia Ltd (ASX: BAL) is expected to receive its accreditation later this year.

Should you invest in Wattle Health?

I think Wattle Health is a very exciting company and well worth keeping a close eye on. If this announcement is in fact the successful receipt of its CFDA accreditation then I expect its shares could rocket when they come out of their trading halt.

However, accreditation merely allows the products to be sold in China, it doesn’t necessarily guarantee sales.

In light of this, I plan to hold out to see how its products resonate with Chinese consumers and whether its sales growth justifies the premium its shares are trading at.

In the meantime I think these high-flying blue chip shares could provide strong returns for investors this year.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of A2 Milk. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…


The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!